Detailed information for compound 1949383

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 393.775 | Formula: C17H14ClF2N5O2
  • H donors: 2 H acceptors: 3 LogP: 1.67 Rotable bonds: 5
    Rule of 5 violations (Lipinski): 1
  • SMILES: FC[C@]1(N=C(N)O[C@@H]2[C@H]1C2)c1nc(ccc1F)NC(=O)c1ccc(cn1)Cl
  • InChi: 1S/C17H14ClF2N5O2/c18-8-1-3-11(22-6-8)15(26)24-13-4-2-10(20)14(23-13)17(7-19)9-5-12(9)27-16(21)25-17/h1-4,6,9,12H,5,7H2,(H2,21,25)(H,23,24,26)/t9-,12+,17-/m1/s1
  • InChiKey: MELWCFRTFXQYNP-CIBPLQMKSA-N  

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Onchocerca volvulus Matrix metalloproteinase homolog 0.0137 0 0.5
Loa Loa (eye worm) angiotensin-converting enzyme family protein 0.0622 1 1
Onchocerca volvulus Matrilysin homolog 0.0137 0 0.5
Schistosoma mansoni memapsin-2 (A01 family) 0.0521 0.7923 0.5
Loa Loa (eye worm) matrixin family protein 0.0149 0.0254 0.0254
Echinococcus granulosus matrix metallopeptidase 7 M10 family 0.0224 0.1799 0.5
Echinococcus multilocularis matrix metallopeptidase 7 (M10 family) 0.0224 0.1799 0.5
Wolbachia endosymbiont of Brugia malayi extracellular metallopeptidase 0.0303 0.3435 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 39340 nM BindingDB_Patents: Fluorescence Resonance Energy Transfer Assay. The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSO final, 100 uM genapol (which is a nonionic detergent, below its Critical Micelle Concentration). The Beta Secretase enzyme (0.2 nM) is pre-incubated for one hour with inhibitors, typically in about 1 uL of DMSO according to a serial dilution, are added thereto. This assay is effectively started by the addition of FRET substrate (50 nM) and the combination is incubated for one hour. The FRET assay is terminated with by addition of Tris buffer, which raises the pH to neutrality, and the fluorescence is determined. The FRET substrate is a peptide with commercially available fluorophore and quencher, on opposite sides of the BACE cleavage site. Proteolytic cleavage of the FRET substrate releases quenching of fluorescence (excitation 488 nm and emission 425 nm). ChEMBL. No reference
IC50 (binding) = 1616000 nM BindingDB_Patents: Fluorescence Resonance Energy Transfer Assay. Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme (9 nM) is pre-incubated for one hour with inhibitors, typically in about 1 uL of DMSO according to a serial dilution, is added thereto. The assays are effectively started by the addition of different FRET substrates (20 nM for Cat D) and the combination is incubated for one hour. The FRET assay is terminated with by addition of Tris buffer, which raises the pH to neutrality, and the fluorescence is determined. The FRET substrate is a peptide with commercially available fluorophore and quencher, on opposite sides of the BACE cleavage site. The Cat D substrate peptide sequence is based on sequence #1 of Table 1 from Gulnik et al. FEBS Letters v413 p379-384 1997. Proteolytic cleavage of the FRET substrate releases quenching of fluorescence (Cat D excitation 500 nm and emission 580 nm). ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

No external resources registered for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.